Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Active not recruiting 2Withdrawn 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Breast Neoplasms 4354Neoplasms 3056Prostatic Neoplasms 1904Colorectal Neoplasms 1739Lung Neoplasms 1555Carcinoma, Non-Small-Cell Lung 1270Pancreatic Neoplasms 981Leukemia, Myeloid, Acute 952Multiple Myeloma 951Lymphoma 912Head and Neck Neoplasms 894Leukemia 852Precursor Cell Lymphoblastic Leukemia-Lymphoma 833Neoplasm Metastasis 793Colonic Neoplasms 785Carcinoma, Hepatocellular 762Ovarian Neoplasms 757Melanoma 752Stomach Neoplasms 742Rectal Neoplasms 701Brain Neoplasms 696Lymphoma, Non-Hodgkin 663Leukemia, Lymphocytic, Chronic, B-Cell 618Uterine Cervical Neoplasms 607Lymphoma, Follicular 559Glioblastoma 541Recurrence 539Hodgkin Disease 532Esophageal Neoplasms 527Myelodysplastic Syndromes 508

Interventions

Lenalidomide 1Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × OTHER × Lymphomatoid Papulosis × Clear all
NCT03409432 2025-07-25

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
26 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡